Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September
The miniseries topics are as follows:
September 11: A discussion of the patient journey and treatment paradigm in allogeneic bone marrow transplant featuring Steven Devine, M.D., Chief Medical Officer, Be The Match BioTherapies, National Marrow Donor Program®/Be The Match®, and Associate Scientific Director, the CIBMTR® ( Center for International Blood and Marrow Transplant Research®)
September 23: A discussion of the healthcare economics of bone marrow transplant featuring Krishna Komanduri, M.D., Kalish Family Chair in Stem Cell Transplantation and Chief, Division of Transplantation and Cellular Therapyat the Sylvester Comprehensive Cancer Center, University of Miami
Each webcast will be available on the “Investors & Media” section of the
Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). In both Phase 1/2 and Phase 3 clinical studies (NCT01816230 and NCT02730299), omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated.1,2 Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit www.clinicaltrials.gov.
Omidubicel is an investigational therapy, and its safety and efficacy has not been evaluated by the
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the anticipated timing of data disclosures and regulatory filing submissions, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the ongoing global COVID-19 pandemic and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the
1Horwitz M.E., Wease S., Blackwell B., Valcarcel D. et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019 Feb 10;37(5):367-374.